Willingness to Receive COVID-19 Vaccination in Japan
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lu, H.; Stratton, C.W.; Tang, Y.-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Virol. 2020, 92, 401–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- World Health Organization. WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020; WHO: Geneva, Switzerland, 2020. [Google Scholar]
- Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- American Medical Association. AMA Announces Vaccine-Specific CPT Codes for Coronavirus Immunizations. Available online: https://www.ama-assn.org/press-center/press-releases/ama-announces-vaccine-specific-cpt-codes-coronavirus-immunizations (accessed on 30 November 2020).
- Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020, 395, 1845–1854. [Google Scholar] [CrossRef]
- Bucci, E.; Andreev, K.; Björkman, A.; Calogero, R.A.; Carafoli, E.; Carninci, P.; Castagnoli, P.; Cossarizza, A.; Mussini, C.; Guerin, P.; et al. Safety and efficacy of the Russian COVID-19 vaccine: More information needed. Lancet 2020, 396, e53. [Google Scholar] [CrossRef]
- Caddy, S. Russian SARS-CoV-2 vaccine. BMJ 2020, 370, m3270. [Google Scholar] [CrossRef]
- Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, P.P.; Brouwer, W.; Van Exel, J.; Schreyögg, J.; Stargardt, T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur. J. Health Econ. 2020, 21, 977–982. [Google Scholar] [CrossRef]
- Dubé, E.; Laberge, C.; Guay, M.; Bramadat, P.; Roy, R.; Bettinger, J.A. Vaccine hesitancy. Hum. Vaccines Immunother. 2013, 9, 1763–1773. [Google Scholar] [CrossRef]
- Macdonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef]
- Marti, M.; De Cola, M.; Macdonald, N.E.; Dumolard, L.; Duclos, P. Assessments of global drivers of vaccine hesitancy in 2014—Looking beyond safety concerns. PLoS ONE 2017, 12, e0172310. [Google Scholar] [CrossRef] [Green Version]
- Hamed, T. Determining Sample Size; How to Calculate Survey Sample Size. Int. J. Econ. Manag. Syst. 2017, 2, 237–239. [Google Scholar]
- Bartlett, J.E.; Kotrlik, J.; Higgins, C. Organizational Research: Determining Appropriate Sample Size in Survey Research. Inf. Technol. Learn. Perform. J. 2001, 19, 43–50. [Google Scholar]
- Yagi, A.; Ueda, Y.; Tanaka, Y.; Nakae, R.; Kakubari, R.; Morimoto, A.; Terai, Y.; Ohmichi, M.; Ichimura, T.; Sumi, T.; et al. Time-dependent changes of the intention of mothers in Japan to inoculate their daughters with the HPV vaccine after suspension of governmental recommendation. Hum. Vaccines Immunother. 2018, 14, 2497–2502. [Google Scholar] [CrossRef] [Green Version]
- Darden, P.M.; Thompson, D.M.; Roberts, J.; Hale, J.J.; Pope, C.; Naifeh, M.; Jacobson, R.M. Reasons for Not Vaccinating Adolescents: National Immunization Survey of Teens, 2008–2010. Pediatrics 2013, 131, 645–651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, M.C.S.; Lee, A.; Ngai, K.L.K.; Chor, J.C.Y.; Chan, P.K. Knowledge, Attitude, Practice and Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among Primary Care Physicians in Hong Kong. PLoS ONE 2013, 8, e71827. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sotiriadis, A.; The LYSISTRATA Study Group; Dagklis, T.; Siamanta, V.; Chatzigeorgiou, K.; Agorastos, T. Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch. Gynecol. Obstet. 2012, 285, 1719–1724. [Google Scholar] [CrossRef]
- Hirota, Y.; Kaji, M. Scepticism about influenza vaccine efficacy in Japan. Lancet 1994, 344, 408–409. [Google Scholar] [CrossRef]
- Hirota, Y.; Kaji, M. History of influenza vaccination programs in Japan. Vaccine 2008, 26, 6451–6454. [Google Scholar] [CrossRef]
- Nawa, N.; Kogaki, S.; Takahashi, K.; Ishida, H.; Baden, H.; Katsuragi, S.; Narita, J.; Tanaka-Taya, K.; Ozono, K. Analysis of public concerns about influenza vaccinations by mining a massive online question dataset in Japan. Vaccine 2016, 34, 3207–3213. [Google Scholar] [CrossRef]
- Zhan, S.; Yang, Y.Y.; Fu, C. Public’s early response to the novel coronavirus–infected pneumonia. Emerg. Microbes Infect. 2020, 9, 534. [Google Scholar] [CrossRef] [Green Version]
- Statistics Bureau of Japan. Chapter 2. Population and Households Japan Statistical Yearbook; Statistics Bureau of Japan: Tokyo, Japan, 2017; p. 60.
- Hiraishi, K.; Miura, A.; Nakanishi, D.; Yamagata, M.; Ortolani, A. Disgust Sensitivity and COVID-19. Available online: osf.io/9cbhr (accessed on 30 November 2020).
- Muto, K.; Yamamoto, I.; Nagasu, M.; Tanaka, M.; Wada, K. Japanese citizens’ behavioral changes and preparedness against COVID-19: An online survey during the early phase of the pandemic. PLoS ONE 2020, 15, e0234292. [Google Scholar] [CrossRef] [PubMed]
- Thomson, A.; Watson, M. Vaccine hesitancy: A vade mecum v1.0. Vaccine 2016, 34, 1989–1992. [Google Scholar] [CrossRef] [PubMed] [Green Version]
N | % | ||
---|---|---|---|
Gender | Male | 584 | 53.1 |
Female | 516 | 46.9 | |
Age group | under 19 | 136 | 12.4 |
20–29 | 211 | 19.2 | |
30–39 | 155 | 14.1 | |
40–49 | 161 | 14.6 | |
50–59 | 152 | 13.8 | |
60–69 | 118 | 10.7 | |
over 70 | 167 | 15.2 | |
Chronic condition | None | 817 | 74.3 |
1+ | 283 | 25.7 | |
Place of residence | Central | 645 | 58.6 |
Others | 455 | 41.4 |
Yes (%) | Unsure (%) | No (%) | p * | ||
---|---|---|---|---|---|
Gender | Male | 397 (68.0) | 109 (18.6) | 78 (13.4) | 0.014 |
Female | 326 (63.2) | 133 (25.8) | 57 (11.0) | ||
Age group | under 19 | 94 (69.1) | 28 (20.6) | 14 (10.3) | 0.002 |
20–29 | 134 (63.5) | 59 (28.0) | 18 (8.5) | ||
30–39 | 100 (64.5) | 33 (21.3) | 22 (14.2) | ||
40–49 | 92 (57.1) | 45 (28.0) | 24 (14.9) | ||
50–59 | 98 (64.5) | 25 (16.5) | 29 (19.0) | ||
60–69 | 76 (64.4) | 28 (23.7) | 14 (11.9) | ||
over 70 | 129 (77.2) | 24 (14.4) | 14 (8.4) | ||
(Repost) | <20 | 94 (69.1) | 28 (20.6) | 14 (10.3) | 0.061 |
20–59 | 424 (62.4) | 162 (23.9) | 93 (13.7) | ||
>60 | 205 (71.9) | 52 (18.3) | 28 (9.8) | ||
Chronic condition | None | 501 (61.3) | 205 (25.1) | 111 (13.6) | <0.001 |
1 or more | 222 (78.4) | 37 (13.1) | 24 (8.5) | ||
Place of residence | Central | 403 (62.5) | 155 (24.0) | 87 (13.5) | 0.026 |
Others | 320 (70.3) | 87 (19.1) | 48 (10.6) |
AOR | 95% CI | p | ||
---|---|---|---|---|
Gender | Male | 1 | - | |
Female | 1.496 | 1.108–2.020 | 0.008 | |
Age | 0.991 | 0.983–0.998 | 0.025 | |
Chronic condition | One or more | 1 | - | |
None | 1.935 | 1.323–2.831 | <0.001 | |
Place of residence | Others | 1 | - | |
Central | 1.935 | 1.156–2.121 | 0.003 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoda, T.; Katsuyama, H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines 2021, 9, 48. https://doi.org/10.3390/vaccines9010048
Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines. 2021; 9(1):48. https://doi.org/10.3390/vaccines9010048
Chicago/Turabian StyleYoda, Takeshi, and Hironobu Katsuyama. 2021. "Willingness to Receive COVID-19 Vaccination in Japan" Vaccines 9, no. 1: 48. https://doi.org/10.3390/vaccines9010048
APA StyleYoda, T., & Katsuyama, H. (2021). Willingness to Receive COVID-19 Vaccination in Japan. Vaccines, 9(1), 48. https://doi.org/10.3390/vaccines9010048